Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
Anti-Retroviral Agents
/ administration & dosage
Darunavir
/ administration & dosage
Drug Interactions
Drug Monitoring
Female
HIV Infections
/ drug therapy
HIV-1
/ drug effects
Heterocyclic Compounds, 3-Ring
/ administration & dosage
Humans
Male
Middle Aged
Nitriles
Oxazines
Piperazines
Pyridazines
/ administration & dosage
Pyridones
Pyrimidines
Quinolones
/ administration & dosage
Journal
Antiviral therapy
ISSN: 2040-2058
Titre abrégé: Antivir Ther
Pays: England
ID NLM: 9815705
Informations de publication
Date de publication:
2019
2019
Historique:
accepted:
30
09
2018
pubmed:
26
10
2018
medline:
24
3
2020
entrez:
25
10
2018
Statut:
ppublish
Résumé
We report the cases of two treatment-experienced HIV-infected patients with complex antiretroviral regimens that showed significant drug-drug interactions with etravirine. Unexpectedly high etravirine concentrations likely caused subtherapeutic levels of darunavir, elvitegravir and dolutegravir through concentration-dependent metabolic induction. Therapeutic drug monitoring allowed safe etravirine dose decreases to manage these interactions.
Substances chimiques
Anti-Retroviral Agents
0
Heterocyclic Compounds, 3-Ring
0
Nitriles
0
Oxazines
0
Piperazines
0
Pyridazines
0
Pyridones
0
Pyrimidines
0
Quinolones
0
etravirine
0C50HW4FO1
elvitegravir
4GDQ854U53
dolutegravir
DKO1W9H7M1
Darunavir
YO603Y8113
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM